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Survivors of childhood cancer are at increased risk for a wide range of late effects. However,
no large population-based studies have included the whole range of somatic diagnoses
including subgroup diagnoses and all main types of childhood cancers. Therefore, we
aimed to provide the most detailed overview of the long-term risk of hospitalisation in survi-
vors of childhood cancer.
Methods and findings
From the national cancer registers of Denmark, Finland, Iceland, and Sweden, we identified
21,297 5-year survivors of childhood cancer diagnosed with cancer before the age of 20
years in the periods 1943–2008 in Denmark, 1971–2008 in Finland, 1955–2008 in Iceland,
and 1958–2008 in Sweden. We randomly selected 152,231 population comparison individu-
als matched by age, sex, year, and country (or municipality in Sweden) from the national
population registers. Using a cohort design, study participants were followed in the national
hospital registers in Denmark, 1977–2010; Finland, 1975–2012; Iceland, 1999–2008; and
Sweden, 1968–2009. Disease-specific hospitalisation rates in survivors and comparison
individuals were used to calculate survivors’ standardised hospitalisation rate ratios (RRs),
absolute excess risks (AERs), and standardised bed day ratios (SBDRs) based on length of
stay in hospital. We adjusted for sex, age, and year by indirect standardisation. During
336,554 person-years of follow-up (mean: 16 years; range: 0–42 years), childhood cancer
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survivors experienced 21,325 first hospitalisations for diseases in one or more of 120 dis-
ease categories (cancer recurrence not included), when 10,999 were expected, yielding an
overall RR of 1.94 (95% confidence interval [95% CI] 1.91–1.97). The AER was 3,068
(2,980–3,156) per 100,000 person-years, meaning that for each additional year of follow-up,
an average of 3 of 100 survivors were hospitalised for a new excess disease beyond the
background rates. Approximately 50% of the excess hospitalisations were for diseases of
the nervous system (19.1% of all excess hospitalisations), endocrine system (11.1%), diges-
tive organs (10.5%), and respiratory system (10.0%). Survivors of all types of childhood can-
cer were at increased, persistent risk for subsequent hospitalisation, the highest risks being
those of survivors of neuroblastoma (RR: 2.6 [2.4–2.8]; n = 876), hepatic tumours (RR: 2.5
[2.0–3.1]; n = 92), central nervous system tumours (RR: 2.4 [2.3–2.5]; n = 6,175), and Hodg-
kin lymphoma (RR: 2.4 [2.3–2.5]; n = 2,027). Survivors spent on average five times as many
days in hospital as comparison individuals (SBDR: 4.96 [4.94–4.98]; n = 422,218). The anal-
yses of bed days in hospital included new primary cancers and recurrences. Of the total
422,218 days survivors spent in hospital, 47% (197,596 bed days) were for new primary
cancers and recurrences. Our study is likely to underestimate the absolute overall disease
burden experienced by survivors, as less severe late effects are missed if they are treated
sufficiently in the outpatient setting or in the primary health care system.
Conclusions
Childhood cancer survivors were at increased long-term risk for diseases requiring inpatient
treatment even decades after their initial cancer. Health care providers who do not work in
the area of late effects, especially those in primary health care, should be aware of this
highly challenged group of patients in order to avoid or postpone hospitalisations by preven-
tion, early detection, and appropriate treatments.
Author summary
Why was this study done?
• Today, four out of five children with cancer become long-term survivors. However, as
toxic treatments, often in combination, are given at an age distinguished by growth and
organ maturation, many childhood cancer survivors face significant and often unchar-
acterised late somatic morbidities.
• No previous study has been able to examine the long-term inpatient morbidity in child-
hood cancer survivors including virtually all combinations of type of childhood cancer
and disease-specific outcome.
What did the researchers do and find?
• We explored the lifetime somatic morbidity pattern in 21,297 5-year survivors of child-
hood cancer using the unique health registries of the Nordic countries, including 120
disease entities and all main diagnostic groups of childhood cancer.
Long-term inpatient disease burden in childhood cancer survivors
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• We found that survivors had an overall 2-fold risk of being hospitalised and experienced
longer stays in hospital than population comparisons of similar age and sex.
• Major reasons for hospitalisation among cancer survivors were diseases of the nervous
system (19.1% of all excess hospitalisations), endocrine system (11.1%), digestive organs
(10.5%), and respiratory system (10.0%). Together, these four groups of diseases
accounted for 51% of the excess cause-specific hospitalisations among cancer survivors.
• The morbidity pattern was highly dependent on the type of childhood cancer, with
highest risks seen for survivors of neuroblastoma, hepatic and central nervous system
(CNS) tumours, and Hodgkin lymphoma.
What do these findings mean?
• This study provides a comprehensive overview of the lifelong, complex, and often seri-
ous disease pattern that childhood cancer patients encounter after ended treatment.
• As we have used diagnostic inpatient information as measure of outcomes, our study
presents the most serious somatic disease burden, which, in combination with previ-
ously described cognitive and other psychological adverse effects, may have significant
impact on the quality of life and overall mortality of childhood cancer survivors.
• Clinicians in primary and secondary health care should be aware of this vulnerable
group of patients for better detection, prevention, and management of treatment-
induced late effects.
• We recommend long-term follow-up of high-risk subsets of childhood cancer survivors
in a specialised setting.
Introduction
The number of childhood cancer survivors is increasing steadily in many parts of the world
because of the extraordinary improvement in survival rates during the past five decades [1]. In
the Nordic countries, four of five childhood cancer patients can expect to be long-term survi-
vors [2]. These major improvements in survival come, however, at a price. Because of intense
exposure to radiation and highly toxic compounds during treatment, a high proportion of sur-
vivors of childhood cancer now face somatic, mental, and cognitive late effects, many of which
become clinically apparent even decades after the cancer was cured [3–7]. Only a limited num-
ber of studies have investigated the hospitalisation pattern subsequent to treatment for cancer
diagnosed during childhood, adolescence, and young adulthood [8–13]. They all revealed an
overall increased risk for hospitalisation. However, the record linkage studies with diagnostic
inpatient information [9,10,12,13] were limited by study size and unable to give reliable risk
estimates for rare types of childhood cancer or combinations of types of childhood cancer and
types of subsequent disease. The larger studies were either based on self-reported information
on causes for hospitalisation [7] or questionnaire data from patients’ primary health care phy-
sicians [10], with a relatively large proportion of survivors lost to follow-up.
In a population-based cohort study with virtually no loss to follow-up and exclusive use of
medically verified diagnostic information from individual inpatient records, we studied the
Long-term inpatient disease burden in childhood cancer survivors
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full range of somatic morbid conditions requiring hospitalisation in 21,297 5-year survivors of
childhood cancer diagnosed between 1943–2008. As this is the largest long-term follow-up
study of inpatient care among childhood cancer survivors conducted so far, it allowed stratifi-
cations and detailed analyses that were not possible in previous studies and provides novel
information on diseases that first become symptomatic in middle age or senescence. Thus, the
primary aim of our study was to present a comprehensive yet detailed overview of the long-
term frequency and distribution of somatic diseases serious enough to require hospitalisations
in survivors of childhood cancer combined and by type of cancer.
Methods
Cancer survivor and comparison cohorts
This retrospective, register-based cohort study is part of the collaborative study Adult Life after
Childhood Cancer in Scandinavia (ALiCCS) (www.aliccs.org) [14]. The ALiCCS study was
approved by the national bioethics committee, the data protection authority, or the national
institute for health and welfare in the respective countries (Denmark: 2010-41-4334; Finland:
THL/520/5.05.00/2016; Iceland: VSN 10–041; and Sweden: O¨ 10–2010, 2011/19). Consent
from study participants was not required as all data were available in national health registers.
The basic childhood cancer cohort in the present analysis is a subcohort of the Nordic
ALiCCS material, comprising 33,576 individuals with cancer diagnosed in Denmark, Finland,
Iceland, or Sweden in people under the age of 20 years in the periods 1943–2008 in Denmark,
1971–2008 in Finland, 1955–2008 in Iceland, and 1958–2008 in Sweden (Fig 1) [15–18].
Patients from Norway were not included, as complete hospitalisation histories with all diseases
included in the present study were not available. From the cancer registries, we obtained each
patient’s personal identification number, date of diagnosis, and type of cancer and assigned
patients to the 12 main diagnostic groups of the International Classification Scheme for Child-
hood Cancer, with lymphoma divided further into Hodgkin, non-Hodgkin lymphoma, and
other lymphomas [19]. For each childhood cancer patient, we randomly selected five compari-
son individuals from the national population registers who were alive on the date of the cancer
diagnosis of the corresponding patient; of the same sex, age, and country; and without a cancer
diagnosis before the age of 20 years. Fewer than five comparison individuals were available for
157 patients, leaving 167,712 participants for study. For both patients and comparison individ-
uals, we obtained information from the population registers on vital status and emigration
during follow-up.
Before linkage of study participants to the respective national hospital registers, we excluded
those in whom more than one cancer was diagnosed during childhood, those who had died or
emigrated before the start of the national hospital registers (Sweden, stepwise inclusion of coun-
ties in 1964–1987 and nationwide since 1987; Finland, 1975; Denmark, 1977; Iceland, 1999),
and those who had died or emigrated within 5 years of the date of cancer diagnosis or an equiv-
alent time lag for the population comparisons. These exclusions resulted in cohorts of 21,518
5-year childhood cancer survivors and 152,481 population comparison individuals (Fig 1).
Hospital admissions
The nationwide hospital registries hold information on all nonpsychiatric hospital admissions
in the four countries [20,21]. Registration is mandatory, and the treating physician submits
diagnostic information electronically. Each admission to a hospital initiates a record, which
includes the personal identification number of the patient, the dates of admission and dis-
charge, a primary discharge diagnosis, and supplementary diagnoses coded according to the
International Classification of Diseases 7th–10th revisions (ICD-7–ICD-10).
Long-term inpatient disease burden in childhood cancer survivors
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Fig 1. Flow diagram of exclusions of study participants and final study cohort size. Note: the index date is the date of cancer
diagnosis and the corresponding date for population comparisons.
https://doi.org/10.1371/journal.pmed.1002296.g001
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Data on cancer survivors and comparison individuals were linked to the hospital registers,
and a full hospital history with discharge diagnoses was established for each person with a pre-
vious hospital contact. We excluded cancer survivors and comparison individuals who had
ever been hospitalised with a congenital malformation or chromosome abnormality (ICD-8
codes 740–759, ICD-10 codes Q00–Q99), as this could possibly confound the associations
between childhood cancer and several of the outcomes, leaving 21,297 5-year survivors of
childhood cancer and 152,231 population comparison individuals for the risk analysis (Fig 1).
To quantify the inpatient disease burden among study participants comprehensibly, we
grouped the hospital discharge diagnoses into 120 disease categories or diagnoses, which in
turn were assembled into 12 main diagnostic groups (S1 Table). The 12 main diagnostic
groups were mutually exclusive; all neoplasms were grouped in the two main diagnostic
groups of malignant neoplasms and benign neoplasms. Diagnoses coded according to ICD-7,
ICD-9, and ICD-10 were adapted to ICD-8 to the extent possible, as shown in the table. We
did not include the ICD sections of ill-defined diseases and the group of injuries and violence
in the analysis, as these were regarded as too unspecific for solid conclusions. Mental disorders
were the focus of a previous study [3], and childbirth and pregnancy complications require
special considerations and will be investigated in separate publications.
Statistical analysis
Follow-up for diseases other than cancer was started 5 years after the date of cancer diagnosis
for the cancer survivors and the corresponding date for the comparison individuals or at the
beginning of the hospital registers (Denmark, 1977; Finland, 1975; Iceland, 1999; Sweden,
from 1968–1987 stepwise inclusion of counties and nationwide since 1987), whichever
occurred later. Follow-up for a second cancer in survivors and a first cancer in comparisons
started at age 20 years at the earliest. Follow-up ended on the date of death, the date of emigra-
tion, or the end of the study (Iceland: 31 December 2008; Sweden: 31 December 2009; Den-
mark: 31 October 2010; Finland: 31 December 2012), whichever occurred first. As hospital
registers do not reliably distinguish hospitalisations due to a relapse from those due to a pri-
mary cancer, we used the cancer registries for information on second primary cancers among
childhood cancer survivors and first primary cancers among comparison individuals in analy-
ses of hospitalisation risk. Thus, hospitalisations with childhood cancer recurrence were not
included in the main analyses of hospitalisation risk.
Only the primary diagnosis, i.e., the main reason for hospitalisation at each inpatient con-
tact, was included in the analyses. If participants had more than one hospital admission for a
particular disease category, only the first record was retained. Risk was analysed for each of the
120 disease categories, and the numbers of first hospitalisations for somatic diseases in differ-
ent categories were added up for the 12 main diagnostic groups. For each person, the final sum
yielded the total number of first hospitalisations for diseases requiring hospitalisation in differ-
ent categories. The observed number of first hospital admissions of survivors of childhood
cancer for a given disease category was compared with expected numbers derived from the
appropriate sex-, age-, and calendar period-specific hospitalisation rates of the comparison
cohort, and the standardised hospitalisation rate ratios (RRs) were estimated. The significance
and 95% confidence intervals (95% CIs) were computed using Fieller’s theorem and assuming
that the observed number of first hospital contacts follows a Poisson distribution [22]. The
absolute excess risk (AER), i.e., the additional risk for hospitalisation above background levels,
was derived as the difference between the observed and expected first hospitalisation rates for
a particular disease category per 100,000 person-years of follow-up. We did not stratify analy-
ses by ethnicity, because this variable is not available in the Nordic population registers.
Long-term inpatient disease burden in childhood cancer survivors
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Table 1. Characteristics of the study population of 21,297 5-year childhood cancer survivors in four
Nordic countries.
Characteristic n %





























Hodgkin lymphoma 1,773 8.3
Non-Hodgkin lymphoma 1,193 5.6
Other lymphomas 205 1.0
Central nervous system tumours 4,973 23.4
Neuroblastoma 813 3.8
Retinoblastoma 578 2.7
Renal tumours 969 4.5
Hepatic tumours 117 0.5
Bone tumours 818 3.8
Soft-tissue sarcomas 1,373 6.4
Germ-cell neoplasms 1,502 7.1
Carcinomas 2,567 12.1




End of follow-up (alive) 18,784 88.2
https://doi.org/10.1371/journal.pmed.1002296.t001
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However, the group of non-white individuals is historically of limited size in the Nordic coun-
tries and especially so among children.
Using the same methods as for the RR, we also added up the total number of bed days spent
in hospital for cancer survivors and the number expected had they had the sex-, age-, and cal-
endar period-specific bed day rates of the comparison individuals. We thus derived standard-
ised bed day ratios (SBDRs) for cancer survivors. In the analyses of bed days, we included not
only the first hospitalisation for a given disease category but all hospitalisations for diseases of
the ICD sections of interest. Bed days for cancer recurrences were included in the analyses of
SBDR.
Results
Table 1 gives the main characteristics of the 21,297 5-year childhood cancer survivors included
in the analysis. The survivors were monitored in the national hospital registers for 336,554 per-
son-years (mean: 16 years; range: 0–42 years). Of the survivors, 27% (5,655/21,297) and 12%
(2,546/21,297) were followed beyond the ages of 40 and 50 years, respectively.
Overall, 9,698 (45.5%) childhood cancer survivors were ever admitted to hospital for
somatic disease, when 5,399.2 (25.4%) were expected, yielding an RR of 1.80 (1.76–1.84). The
9,698 survivors ever hospitalised experienced 21,325 first admissions to hospital for diseases in
one or more of the 120 disease categories listed in S1 Table, when 10,999.0 were expected,
yielding an overall RR for a new category-specific admission of 1.94 (Table 2). The underlying
RRs were 1.83 (1.78–1.87) in Denmark, 1.87 (1.82–1.92) in Finland, 1.64 (1.35–1.99) in Ice-
land, and 2.10 (2.05–2.15) in Sweden. Based on the observed and expected hospitalisation rates
of 6,336.3 and 3,268.1 per 100,000 person-years, respectively, the AER of survivors for a new
category-specific admission to hospital was 3,068 per 100,000 person-years (Table 2). Thus, for
each additional year of follow-up, approximately 3 of 100 survivors of childhood cancer were
Table 2. Observed and expected numbers of hospitalisations by sex and attained age in 21,297 5-year survivors of childhood cancer in the Nordic
countries.
5-year cancer survivors (n) Disease-specific
hospitalisationsa
RR (95% CI) Hospitalisation ratesb AERb (95% CI)
Observed Expected Observed Expected
Total 21,297 21,325 10,999.0 1.94 (1.91–1.97) 6,336.3 3,268.1 3,068 (2,980–3,156)
Sex
Male 11,255 10,360 5,211.0 1.99 (1.95–2.03) 5,920.7 2,978.0 2,943 (2,825–3,060)
Female 10,042 10,965 5,788.0 1.89 (1.86–1.93) 6,786.4 3,582.3 3,204 (3,073–3,335)
Attained age (years)
5–9 5,258c 1,105 327.5 3.4 (3.1–3.6) 8,081.4 2,395.0 5,686 (5,201–6,172)
10–19 11,420 4,560 1,881.3 2.4 (2.3–2.5) 6,157.9 2,540.5 3,617 (3,434–3,801)
20–29 14,344 6,260 3,286.9 1.9 (1.9–2.0) 5,619.9 2,950.8 2,669 (2,525–2,813)
30–39 10,644 4,420 2,442.3 1.8 (1.8–1.9) 5,723.7 3,162.7 2,561 (2,387–2,735)
40–49 5,625 2,765 1,596.5 1.7 (1.7–1.8) 7,177.8 4,144.5 3,033 (2,757–3,309)
50–59 2,542 1,525 925.9 1.6 (1.6–1.7) 9,374.2 5,691.5 3,683 (3,194–4,172)
60 1,062 690 538.6 1.3 (1.2–1.4) 12,712.0 9,922.0 2,790 (1,783–3,797)
95% CI, 95% confidence interval; AER, absolute excess risk; RR, standardised hospitalisation rate ratio.
a Hospitalisations are for a selected set of diseases, and each person may be hospitalised for more than one disease; see Methods for details.
b Hospitalisation rates and AER per 100,000 person—years.
c The number of individuals under follow-up at the start of each age interval. Each individual can contribute risk time in more than one age interval; thus, the
sum of all age groups exceeds 21,297.
https://doi.org/10.1371/journal.pmed.1002296.t002
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hospitalised for a new excess disease. Although the relative risk was significantly increased at
all ages, the degree of increase diminished substantially with increasing age, i.e., from a relative
risk of 3.4 in the age group 5–9 years to 1.3 in survivors aged 60 years or older. The absolute
risk did not show a similar linear decline: after about 5,700 excess category-specific hospitalisa-
tions per 100,000 person-years in the age group 5–9 years, the AERs varied from 2,500 to 3,700
excess hospitalisations per 100,000 person-years for all subsequent age groups.
Fig 2 shows the relative risk for hospitalisation for somatic diseases belonging to each of the
12 main diagnostic groups; the highest risks were seen for diseases of the nervous system and
sense organs (RR: 3.6 [3.4–3.7]), followed by diseases of the blood and blood-forming organs
(RR: 2.8 [2.5–3.2]), endocrine diseases and nutritional deficiencies (RR: 2.8 [2.7–3.0]), and
new primary cancers (RR: 2.6 [2.4–2.8]).
Table 3 shows that the pattern of excess hospitalisations among survivors is dominated by
diseases of the nervous system and sense organs (AER: 603 per 100,000 person-years), followed
by diseases of the endocrine system and nutritional deficiencies (AER: 349 per 100,000 person-
years), diseases of the digestive organs (AER: 330 per 100,000 person-years), and diseases of
the respiratory system (AER: 314 per 100,000 person-years). Together, these four main diag-
nostic groups constituted 50.6% (1,596/3,154) of all new excess hospitalisations, mainly for epi-
lepsy (AER: 199 per 100,000 person-years), diseases of nerves and peripheral ganglia (AER:
157 per 100,000 person-years), pneumonia (AER: 144 per 100,000 person-years), and pituitary
hypofunction (AER: 101 per 100,000 person-years). Table 3 shows the estimated relative and
absolute risks of cancer survivors for each of the main diagnostic groups and a selected num-
ber of disease categories. The full table including all 120 disease categories is presented in S2
Table. Particularly high relative risks were seen for pituitary hypofunction (RR: 72.0; n = 341),
testicular dysfunction (RR: 22..9; n = 19), tumours of the central nervous system (CNS) (RR:
11.8; n = 257), and herpes zoster (RR: 11.2; n = 58).
Fig 3A shows that the slight increase in overall AER seen in childhood cancer survivors
over 40 years of age (Table 1) is due to marked increases in the AERs for diseases of the circula-
tory system, new primary cancers, and respiratory diseases with age. Moreover, the figure
shows that the prevailing diagnostic groups during early life were diseases of the nervous
Fig 2. Risk of hospitalisation for somatic diseases in each of 12 main diagnostic groups. 95% CI, 95% confidence interval; Obs.,
observed; RR, standardised hospitalisation rate ratio.
https://doi.org/10.1371/journal.pmed.1002296.g002
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Table 3. Standardised hospitalisation rate ratios (RRs), absolute excess risks (AERs), and the percentage (%) of total AER for main diagnostic
groups and selected disease categories distinguished by AER 20.
Main diagnostic group Number of hospitalisations1 RR (95% CI) AER (95% CI) % of total AER, (n/N)
Disease category Observed Expected
Infectious and parasitic diseases 1,786 794.6 2.2 (2.1–2.4) 295 (269–320) 9.3% (295/3,154)
Sepsis 294 46.6 6.3 (5.4–7.3) 74 (64–84)
Intestinal infectious diseases 515 278.0 1.9 (1.7–2.0) 72 (58–85)
Infectious hepatitis, HIV infections (only in ICD-9
and ICD-10), and other viral diseases
294 170.4 1.7 (1.5–2.0) 37 (27–48)
Erysipelas 180 70.5 2.6 (2.2–3.0) 33 (25–41)
Other bacterial diseases 121 39.2 3.1 (2.5–3.8) 24 (18–31)
Malignant neoplasms (new primary cancer) 1,211 467.5 2,6 (2,4–2,8) 307 (278–336) 9.7% (307/3,154)
Cancer of the eye, the brain, and other parts of
central nervous system
257 23.1 11.8 (9.8–14.2) 97 (84–110)
Cancer of the breast 182 68.2 2.7 (2.3–3.2) 47 (36–58)
Malignant melanoma of the skin 82 36.6 2,2 (1,8–2,9) 26 (18–32)
Cancer of the digestive organs 128 44.7 2,9 (2,3–3,5) 25 (18–32)
Benign neoplasms 917 380.4 2.4 (2.2–2.6) 159 (141–178) 5.1% (159/3,154)
Endocrine diseases, nutritional deficiencies,
and other metabolic diseases
1,819 645.2 2.8 (2.7–3.0) 349 (323–374) 11.1% (349/3,154)
Pituitary hypofunction 341 4.7 72.0 (51.8–100.1) 101 (90–112)
Other metabolic disorders 268 30.6 8.7 (7.4–10.4) 71 (61–81)
Disorders of other endocrine organs 251 23.2 10.8 (9.0–13.1) 68 (59–78)
Diseases of the thyroid gland 233 77.9 3.0 (2.6–3.5) 46 (37–56)
Abnormal menstruation 272 185.2 1.5 (1.3–1.7) 26 (16–36)
Diseases of the blood and blood-forming
organs
291 103.6 2.8 (2.5–3.2) 56 (46–66) 1.8% (56/3,154)
Anaemias 140 48.2 2.9 (2.4–3.5) 27 (20–34)
Diseases of the nervous system and sense
organs
2,817 788.2 3.6 (3.4–3.7) 603 (571–634) 19.1% (603/3,154)
Epilepsy 741 87.8 8.4 (7.6–9.3) 199 (182–215)
Diseases of the nerves and peripheral ganglia 663 142.9 4.6 (4.2–5.1) 157 (141–172)
Inflammatory and other diseases of the eye 492 152.3 3.2 (2.9–3.6) 103 (89–116)
Migraine and other diseases of the brain and
spinal cord
273 122.4 2.2 (2.0–2.5) 45 (35–55)
Cataract 150 27.3 5.5 (4.5–6.8) 37 (29–44)
Inflammatory diseases of the ear 218 115.2 1.9 (1.6–2.2) 31 (22–40)
Diseases of the circulatory system 1,844 912.8 2.0 (1.9–2.1) 277 (251–302) 8.8% (277/3,154)
Cerebrovascular disease 385 127.3 3.0 (2.7–3.4) 77 (65–89)
Heart failure 157 34.3 4.6 (3.8–5.6) 37 (29–44)
Venous and lymphatic disease 362 267.2 1.4 (1.2–1.5) 29 (17–40)
Ischemic heart disease 230 143.2 1.6 (1.4–1.9) 26 (17–35)
Valvular disease (non-rheumatic) 84 15.8 5.3 (4.0–7.0) 20 (15–26)
Diseases of the respiratory system 2,858 1,801.6 1.6 (1.5–1.7) 314 (282–346) 10.0% (314/3,154)
Pneumonia 737 258.8 2.8 (2.6–3.1) 144 (128–161)
Acute upper respiratory infections 581 438.0 1.3 (1.2–1.4) 43 (28–58)
Bronchitis and emphysema 162 81.6 2.0 (1.7–2.4) 24 (16–32)
Respiratory failure 97 18.3 5.3 (4.1–6.8) 23 (18–29)
Diseases of the digestive organs 3,156 2,044.0 1.5 (1.5–1.6) 330 (296–364) 10.5% (330/3,154)
Diseases of the teeth and supporting structures 375 140.9 2.7 (2.4–3.0) 70 (59–82)
Paralytic ileus and intestinal obstruction 232 43.1 5.4 (4.6–6.4) 57 (48–66)
(Continued )
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system and sense organs and infectious and parasitic diseases. Except for a small peak among
adolescent survivors for hospitalisation for diseases of the endocrine system, the AERs of the
seven remaining main diagnostic groups did not show any appreciable variation by attained
age (Fig 3B).
Survivors of all types of childhood cancers were at significantly increased risk for admission
to hospital for subsequent disease (Fig 4). Survivors of neuroblastoma were at highest risk (RR:
2.6), followed by survivors of hepatic tumours (RR: 2.5), CNS tumours (RR: 2.4), Hodgkin
lymphoma (RR: 2.4), and other lymphomas (RR: 2.3). Panels A—M in S1 Fig show the varia-
tions in the excess hospitalisation patterns among survivors of the 11 main groups of child-
hood cancer and of the two subgroups of lymphoma. For example, slightly more than half of
all excess hospitalisations of survivors of CNS tumours were for subsequent diseases of the ner-
vous system and sense organs and endocrine disorders and nutritional deficiencies, while
infectious and parasitic diseases and diseases of the circulatory system were the primary rea-
sons for hospitalisation of survivors of leukaemia and Hodgkin lymphoma, respectively.
The 9,698 cancer survivors who were ever hospitalised spent a total of 422,218 days in hos-
pital whereas 85,071.7 were expected, yielding an overall SBDR of 4.96 (Table 4). The highest
Table 3. (Continued)
Main diagnostic group Number of hospitalisations1 RR (95% CI) AER (95% CI) % of total AER, (n/N)
Disease category Observed Expected
Other diseases of the digestive system 328 168.0 2.0 (1.7–2.2) 48 (37–59)
Diseases of the gallbladder and biliary ducts 458 312.1 1.5 (1.3–1.6) 44 (31–57)
Diseases of the esophagus 152 57.6 2.6 (2.2–3.2) 28 (21–36)
Diseases of the stomach and duodenum 223 131.8 1.7 (1.5–2.0) 27 (18–36)
Diseases of the urinary system and genital
organs
2,010 1,284.8 1.6 (1.5–1.6) 215 (188–243) 6.8% (215/3,154)
Infections of the urinary system 345 161.8 2.1 (1.9–2.4) 55 (44–66)
Chronic cystic disease and other diseases of the
breast
211 120.5 1.8 (1.5–2.0) 27 (18–36)
Other and unspecified disorders of the urinary
system
135 51.1 2.6 (2.2–3.2) 25 (18–32)
Non-inflammatory disorders of the female genital
tract
359 275.2 1.3 (1.2–1.5) 25 (14–37)
Chronic kidney disease 104 34.0 3.1 (2.4–3.8) 21 (15–27)
Diseases of the skin and subcutaneous tissue 739 384.2 1.9 (1.8–2.1) 105 (89–122) 3.3% (105/3,154)
Other disorders of the skin and subcutaneous
tissue
204 42.0 4.9 (4.1–5.8) 48 (40–57)
Infections of the skin and subcutaneous tissue 341 210.2 1.6 (1.4–1.8) 39 (28–51)
Diseases of the bone, joints, and soft tissue 1,877 1,392.4 1.3 (1.3–1.4) 144 (118–170) 4.6% (144/3,154)
Osteomyelitis and other diseases of the bone and
joints
985 726.3 1.4 (1.3–1.5) 79 (59–99)
Other diseases of the musculoskeletal system 477 330.1 1.4 (1.3–1.6) 44 (31–58)
Arthritis and rheumatism 415 329.5 1.3 (1.1–1.4) 26 (13–38)
95% CI, 95% confidence interval; ICD, International Classification of Diseases. Note: The following chapters in the ICD-8 were not included in these
analyses: 5 (“Psychiatric diseases”), 11 (“Diseases in pregnancy, during birth and perinatal diseases”), 14 (“Congenital malformations”), 15 (“Certain
causes of diseases in the perinatal period and death due to this”), 16 (“Symptoms and ill-defined conditions”), 17 (“Injuries and violence”), and 18 (“External
cause of accident”). Also, diseases with the following ICD-10 codes were not included in the analyses: C97, “Cancer arisen independently at several
locations”; D37–D48, “Non-melanoma skin cancer”; C44, C46.0, “Neoplasms of unknown character”; and E65–E68, “Obesity” (ICD-8: 277 and ICD-9: 278).
1 Number of first-time hospitalisations observed and expected among survivors in defined disease categories.
https://doi.org/10.1371/journal.pmed.1002296.t003
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Fig 3. Absolute excess risks (AERs) for hospitalisation by age (years). (A) Infections, new primary
cancers, and diseases of the nervous system, circulatory system, and respiratory system. Note that follow-up
for new primary cancers started at age 20 years. (B) Benign neoplasms and diseases of the endocrine
system; blood and blood-forming organs; digestive system; urinary and genital system; skin and
subcutaneous system; and bone, joints, and soft tissue.
https://doi.org/10.1371/journal.pmed.1002296.g003
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SBDRs were seen for survivors of hepatic tumours (SBDR: 9.9), followed by survivors of leu-
kaemia (SBDR: 8.9), neuroblastoma (SBDR: 8.4), and CNS tumours (SBDR: 6.9). Fig 5 shows
that most of the days spent by cancer survivors in hospital were for cancer recurrences and
new primary cancers (SBDR: 24.2), followed by diseases of the nervous system and sense
organs (SBDR: 5.8), diseases of blood and blood-forming organs (SBDR: 4.2), and benign neo-
plasms (SBDR: 3.4). The high overall SBDR for diseases of the nervous system and sense
organs was due mainly to a particularly high SBDR of 15.9 (15.5–16.2) for epilepsy. Panels A—
M in S2 Fig show the SBDR distributions for survivors of each of the 11 main groups of child-
hood cancer and the two subgroups of lymphoma, and S3 Fig shows the SBDR distribution for
cancer recurrences and new primary cancers by main group of childhood cancer.
Discussion
This population-based study of 21,297 5-year survivors of childhood cancer in the Nordic
countries gives an extensive overview of the pattern of later somatic conditions that are serious
enough to require inpatient care. The study shows that survivors are hospitalised because of a
new somatic disease twice as often as population comparisons and that they spend five times
as many days in hospital. Although cancer and its treatment may affect practically all organ
systems adversely, the pattern of diseases requiring hospitalisation of survivors varied widely
by type of childhood cancer and by survivors’ attained age. Despite the variations, however,
the important findings are that the majority of childhood cancer survivors are at substantial
risk for late effects requiring inpatient care and that the risk remains increased throughout life.
Our results concur with the mounting evidence of an excess risk for serious long-term mor-
bidity in survivors of childhood cancer. Thus, in a clinical assessment, Geenen et al. identified
chronic late effects in 74.5% of survivors treated in a single institution in The Netherlands
[23]. Using self-reported outcomes, Oeffinger et al. showed that 62.3% of survivors included in
the North American Childhood Cancer Survivor Study (CCSS) experienced at least one
adverse, chronic late effect, equivalent to a 3.3-fold higher risk than their siblings [24]. This
Fig 4. Standardised hospitalisation rate ratios (RRs) of survivors of all types of childhood cancers. 95% CI, 95% confidence interval;
Obs., observed.
https://doi.org/10.1371/journal.pmed.1002296.g004
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result is fairly consistent with the hospitalisation rate ratio for somatic disease of close to 2
seen in our study, taking into account differences in the sources of information and the maxi-
mum age at the end of follow-up (48 years in CCSS, lifelong in the Nordic study). In a later
analysis of the CCSS material, Kurt et al. reported a survivor hospitalisation rate that was 1.6
times higher (95% CI 1.6–1.7) than that derived from a United States National Hospital Dis-
charge Survey covering the period 1992–2005 [8].
In a few newer studies of the risk for late morbidity among survivors of cancer diagnosed
during childhood, adolescence, and young adulthood (age range: 0–24 years), diagnostic infor-
mation from hospital discharge registers was used as the outcome measure [9,10,12,13]. These
studies, conducted in Utah, US; British Columbia, Canada; Scotland; and The Netherlands,
Table 4. Observed and expected numbers of bed days at hospital among 21,297 5-year survivors of childhood cancer and standardised bed day
ratios (SBDRs).
Observed number of bed days Bed day rates per 10 person-years SBDR (95% CI)
Observed Expected
Total 422,218 12.5 2.5 4.96 (4.94–4.98)
Sex
Male 225,488 12.9 2.3 5.5 (5.5–5.5)
Female 196,730 12.2 2.7 4.5 (4.5–4.5)
Age at cancer diagnosis (years)
0–4 107,652 10.4 1.7 6.1 (6.0–6.1)
5–9 77,998 13.4 2.1 6.5 (6.4–6.5)
10–14 86,857 13.1 2.8 4.7 (4.7–4.7)
15–19 149,711 13.8 3.4 4.1 (4.1–4.1)
Cancer type
Leukaemias 76,702 14.4 1.6 8.9 (8.8–9.0)
Hodgkin lymphoma 41,568 16.3 2.7 6.2 (6.1–6.2)
Non-Hodgkin lymphoma 18,719 10.2 2.5 4.1 (4.0–4.1)
Other lymphomas 2,095 7.3 1.5 4.9 (4.7–5.1)
CNS tumours 140,967 17.7 2.5 6.9 (6.9–7.0)
Neuroblastoma 17,750 14.1 1.7 8.4 (8.2–8.5)
Retinoblastoma 5,265 4.1 2.2 1.8 (1.8–1.9)
Renal tumours 11,196 6.4 1.8 3.5 (3.5–3.6)
Hepatic tumours 2,032 14.3 1.4 9.9 (9.5–10.3)
Bone tumours 18,590 13.8 3.1 4.5 (4.4–4.5)
Soft-tissue sarcomas 25,718 10.6 3.2 3.3 (3.2–3.3)
Germ-cell neoplasms 24,435 10.1 2.7 3.7 (3.7–3.8)
Carcinomas 33,439 7.2 3.5 2.0 (2.0–2.1)
Other and unspecified neoplasms 3 742 9.4 2.6 3.6 (3.5–3.7)
Age at hospitalisations (years)
5–9 30,624 22.4 1.1 20.1 (19.7–20.6)
10–19 103,919 14.0 1.4 10.0 (9.9–10.1)
20–29 132,298 11.9 1.9 6.1 (6.1–6.2)
30–39 77,628 10.1 2.5 4.1 (4.0–4.1)
40–49 42,540 11.0 3.9 2.8 (2.8–2.9)
50–59 23,858 14.7 6.5 2.2 (2.2–2.3)
60 11,351 20.9 12.6 1.7 (1.6–1.7)
95% CI, 95% confidence interval; CNS, central nervous system.
https://doi.org/10.1371/journal.pmed.1002296.t004
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included 1,499, 1,374, 5,229, and 1,382 survivors, respectively. They show a similar picture of
substantial excess hospitalisation for a wide range of diseases, with increased cumulative num-
bers of days at hospital, as compared with population comparisons. Because of the substantially
larger sample included in the present study and a follow-up period extending into middle age
and beyond, we are able to provide a more detailed description of subsequent disease for a
broader age range while maintaining relatively narrow 95% confidence limits. One notable dif-
ference between the four studies mentioned above and ours is that they included hospitalisa-
tions for psychiatric diseases, cancer recurrence, congenital abnormalities, injuries, suicide,
and externally caused morbidities in the analysis, and the studies in British Columbia, Utah,
and The Netherlands also included hospitalisations for pregnancy complications and delivery
[9,12,13]. This probably explains the moderately higher overall risks for hospitalisation
reported in those studies.
We used hospital-based diagnoses made by physicians as markers of disease outcome.
Although this approach increased the validity of the diagnostic information, less severe late
effects might have been missed because they were treated sufficiently as hospital outpatients or
in the primary health care system. This implies that we almost certainly underestimate the
absolute overall somatic disease burden experienced by childhood cancer survivors. As this
limitation also applies to the comparison cohort, however, the validity of the relative risk esti-
mates is acceptable, although restricted to conditions that require a hospital contact. Moreover,
we cannot exclude the possibility that our results were affected by better medical surveillance
of the survivors than the population comparisons, which could explain part of the longer hos-
pital stays in the survivors. Not covered by the present study of the somatic disease burden but
important to stress is the fact that many childhood cancer survivors face additional and some-
times significant challenges due to cognitive and other psychological adverse effects from can-
cer and its treatment [3,7].
The information on treatment currently included in the Nordic cancer registries is gener-
ally too crude or absent for meaningful analyses of type and dose of chemotherapy and radia-
tion and specific disease outcomes. Although our study does not attribute causality, this
comprehensive overview provides important clinical information on the lifelong inpatient
Fig 5. Number of bed days at hospital and associated standardised bed day ratios (SBDRs) for diseases in each of the 12 main
diagnostic groups. Note that the diagnostic group “Recurrence and new primary cancers” is beyond the scale, with a standardised
hospitalisation rate ratio (RR) of 24.2. 95% CI, 95% confidence interval; Obs., observed.
https://doi.org/10.1371/journal.pmed.1002296.g005
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disease burden experienced by childhood cancer survivors overall and of a number of patient
characteristics, including type of childhood cancer, type of late effect, sex, and attained age.
Associations, including dose-response effects, between specific treatment regimens and the
risk of selected late effects are being addressed in clinical case-cohort studies within the
ALiCCS cohort [14].
As our study is population based and includes a randomly selected comparison group and
data from high-quality health registers, we consider our results valid for children treated for
cancer in other countries with similar health care systems.
In conclusion, we found that survivors of childhood cancer have a highly increased long-
term disease burden, with a broad range of late effects that require inpatient treatment and
substantially longer stays in hospital as compared with the background population of similar
age and sex. This will inevitably constitute a growing health care challenge for our society,
affecting medical costs, and may profoundly influence the quality of life and life expectancy
of childhood cancer survivors. Our findings underscore the need for continued follow-up of
survivors, with particular focus on survivors of neuroblastoma, hepatic tumours, CNS
tumours, Hodgkin lymphoma, and leukaemia. In particular, primary health care physicians
should be aware of the risk for second primary cancers in patients who are childhood cancer
survivors, as the relative risks for cancers are high and tumours may appear earlier in life
than usual.
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